Olodanrigan

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameOlodanrigan
Drug Alias NamePD-126055EMA401
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II receptor type 2 antagonists
TargetsAngiotensin II receptor type 2
Therapy Area/IndicationsNeuralgia, PostherpeticDiabetic Neuropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[21
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNeuralgia, PostherpeticDiabetic Neuropathies

Other Information

ATC CodeN/A
Related LinksN/A